376 related articles for article (PubMed ID: 22448292)
1. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.
Zompi S; Montoya M; Pohl MO; Balmaseda A; Harris E
PLoS Negl Trop Dis; 2012; 6(3):e1568. PubMed ID: 22448292
[TBL] [Abstract][Full Text] [Related]
2. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.
Puschnik A; Lau L; Cromwell EA; Balmaseda A; Zompi S; Harris E
PLoS Negl Trop Dis; 2013; 7(6):e2274. PubMed ID: 23785536
[TBL] [Abstract][Full Text] [Related]
3. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
4. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
5. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.
Zompi S; Santich BH; Beatty PR; Harris E
J Immunol; 2012 Jan; 188(1):404-16. PubMed ID: 22131327
[TBL] [Abstract][Full Text] [Related]
6. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.
Lai CY; Williams KL; Wu YC; Knight S; Balmaseda A; Harris E; Wang WK
PLoS Negl Trop Dis; 2013; 7(9):e2451. PubMed ID: 24069496
[TBL] [Abstract][Full Text] [Related]
7. Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue.
Andrade P; Narvekar P; Montoya M; Michlmayr D; Balmaseda A; Coloma J; Harris E
J Infect Dis; 2020 Jul; 222(4):590-600. PubMed ID: 32193549
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the human serum antibody response to secondary dengue virus infections.
Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
[TBL] [Abstract][Full Text] [Related]
9. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
10. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
11. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.
Lau L; Green AM; Balmaseda A; Harris E
J Clin Virol; 2015 Aug; 69():63-7. PubMed ID: 26209381
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
[TBL] [Abstract][Full Text] [Related]
13. B-cell responses during primary and secondary dengue virus infections in humans.
Mathew A; West K; Kalayanarooj S; Gibbons RV; Srikiatkhachorn A; Green S; Libraty D; Jaiswal S; Rothman AL
J Infect Dis; 2011 Nov; 204(10):1514-22. PubMed ID: 21930609
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.
Adam A; Woda M; Kounlavouth S; Rothman AL; Jarman RG; Cox JH; Ledgerwood JE; Gromowski GD; Currier JR; Friberg H; Mathew A
J Immunol; 2018 Dec; 201(12):3804-3814. PubMed ID: 30413671
[TBL] [Abstract][Full Text] [Related]
15. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
[TBL] [Abstract][Full Text] [Related]
16. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
[TBL] [Abstract][Full Text] [Related]
17. Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.
Elong Ngono A; Chen HW; Tang WW; Joo Y; King K; Weiskopf D; Sidney J; Sette A; Shresta S
EBioMedicine; 2016 Nov; 13():284-293. PubMed ID: 27746192
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
[TBL] [Abstract][Full Text] [Related]
19. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
